Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|June 15, 2004
ICL suits low to high myopia, according to 3-year results
San Diego-The Implantable Collamer Lens (ICL, STAAR Surgical) appears to be safe and effective for treating low to high myopia based on the 3-year FDA study results. There is, however, a low risk of developing a cataract as a result of implantation, explained Harry Grabow, MD, who reported the findings at the annual meeting of the American Society of Cataract and Refractive Surgery.The criteria for inclusion in the myopic ICL study were –3 to –20 D of spherical equivalent (mean preoperative refraction, –10 D) and up to 2.5 D of cylinder. The refractive results were good with a mean stable postoperative refraction of about –0.5 D.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
2
Eyedaptic launches Eva, an agentic AI visual assistant for patients with retinal disease
3
AAO 2026 recap: Christopher J. Rapuano, MD, on the meeting's themes
4
Practical ways to extend anti-VEGF control in RVO, AMD, and DME
5